MCID: SLP001
MIFTS: 48

Sleeping Sickness

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Sleeping Sickness

MalaCards integrated aliases for Sleeping Sickness:

Name: Sleeping Sickness 12 50 55 3 14
African Trypanosomiasis 12 72 55 3 69
African Sleeping Sickness 12
Trypanosomiasis, African 41
Trypanosomiasis African 51

Characteristics:

Orphanet epidemiological data:

55
african trypanosomiasis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 55  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:10112
ICD10 32 B56 B56.9
ICD9CM 34 086.5
MeSH 41 D014353
NCIt 46 C84541
Orphanet 55 ORPHA3385
MESH via Orphanet 42 D014353
UMLS via Orphanet 70 C0041228
ICD10 via Orphanet 33 B56.0 B56.1 B56.9
UMLS 69 C0041228

Summaries for Sleeping Sickness

NINDS : 50 Encephalitis lethargica is a disease characterized by high fever, headache, double vision, delayed physical and mental response, and lethargy. In acute cases, patients may enter coma. Patients may also experience abnormal eye movements, upper body weakness, muscular pains, tremors, neck rigidity, and behavioral changes including psychosis. The cause of encephalitis lethargica is unknown. Between 1917 to 1928, an epidemic of encephalitis lethargica spread throughout the world, but no recurrence of the epidemic has since been reported. Postencephalitic Parkinson's disease may develop after a bout of encephalitis-sometimes as long as a year after the illness.

MalaCards based summary : Sleeping Sickness, also known as african trypanosomiasis, is related to chagas disease and leishmaniasis. An important gene associated with Sleeping Sickness is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Sulfur amino acid metabolism. The drugs Ornithine and Nifurtimox have been mentioned in the context of this disorder. Affiliated tissues include testes, eye and brain.

Disease Ontology : 12 A trypanosomiasis that results from infection by Trypanosoma brucei and gambiense, which is transmitted by the bite of an infected tsetse fly (Glossina spp). The symptoms include fever, headache, joint pain, itching, confusion, sensory disturbances, poor coordination and sleep disturbances.

CDC : 3 African Trypanosomiasis, also known as "sleeping sickness," is caused by microscopic parasites of the species Trypanosoma brucei. It is transmitted by the tsetse fly (Glossina species), which is found only in rural Africa. Although the infection is not found in the United States, historically, it has been a serious public health problem in some regions of sub-Saharan Africa. Currently, about 10,000 new cases each year are reported to the World Health organization; however, it is believed that many cases go undiagnosed and unreported. Sleeping sickness is curable with medication, but is fatal if left untreated.

Wikipedia : 72 African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans... more...

Related Diseases for Sleeping Sickness

Diseases related to Sleeping Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
# Related Disease Score Top Affiliating Genes
1 chagas disease 30.4 IL10 IL6 NOS2
2 leishmaniasis 30.3 IL10 NOS2 SRM
3 visceral leishmaniasis 29.4 IL10 NOS2 PGD
4 trypanosomiasis 29.4 AMD1 APOL1 HP HPR IL10 IL6
5 malaria 27.7 AMD1 GAPDH HP IL10 IL6 NOS2
6 trypanosomiasis, human east-african 11.5
7 trypanosomiasis, human west-african 11.5
8 von economo's disease 11.1
9 eastern equine encephalitis 10.9
10 eye lymphoma 10.4 IL10 IL6
11 acute transverse myelitis 10.4 IL10 IL6
12 immune suppression 10.4 IL10 IL6
13 anhaptoglobinemia 10.4 HP HPR
14 funisitis 10.3 IL10 IL6
15 autoinflammation, lipodystrophy, and dermatosis syndrome 10.2 IL10 IL6 NOS2
16 chlamydia 10.2 IL10 IL6 NOS2
17 crohn's disease 10.2 HP IL10 IL6
18 anemia, sideroblastic, and spinocerebellar ataxia 10.2 ABCB7 MDH2
19 gastroenteritis 10.2 IL10 IL6 MDH2
20 kala-azar 1 10.1
21 parasitic protozoa infectious disease 10.1 APOL1 HP IL10 IL6
22 nervous system disease 10.1 IL10 IL6 NOS2
23 adult respiratory distress syndrome 10.1 IL10 IL6 TF
24 idiopathic achalasia 10.1 IL10 NOS2
25 urinary system disease 10.1 APOL1 IL6 TF
26 immune system disease 10.1 IL10 IL6 TF
27 interstitial lung disease 10.1 IL10 IL6 TF
28 congenital disorder of glycosylation, type ia 10.1 ABCB7 HP TF
29 atransferrinemia 10.0 ABCB7 HP TF
30 melancholia 10.0 HP TF
31 choroiditis 10.0
32 baylisascariasis 10.0 GAPDH IL10
33 cerebritis 9.9
34 encephalopathy 9.9
35 deficiency anemia 9.9 HP IL6 TF
36 colitis 9.9 IL10 IL6 NOS2
37 eales disease 9.8 IL10 IL6 NOS2 TF
38 dirofilariasis 9.8 AMD1 GAPDH HP
39 blood group, i system 9.7
40 hepatitis c virus 9.7
41 immunodeficiency, common variable, 10 9.7
42 hepatitis 9.7
43 rabies 9.7
44 hepatitis c 9.7
45 hypogonadism 9.7
46 viral encephalitis 9.7
47 neuronitis 9.7
48 narcolepsy 9.7
49 encephalitis 9.7
50 glucosephosphate dehydrogenase deficiency 9.7 HP PGD

Graphical network of the top 20 diseases related to Sleeping Sickness:



Diseases related to Sleeping Sickness

Symptoms & Phenotypes for Sleeping Sickness

Drugs & Therapeutics for Sleeping Sickness

Drugs for Sleeping Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ornithine Approved, Nutraceutical Phase 4,Phase 2,Phase 3 70-26-8, 3184-13-2 6262
2 Nifurtimox Investigational Phase 4,Phase 2,Phase 3 23256-30-6
3 Anti-Infective Agents Phase 4,Phase 2,Phase 3
4 Antiparasitic Agents Phase 4,Phase 2,Phase 3
5 Antiprotozoal Agents Phase 4,Phase 2,Phase 3
6 Melarsoprol Investigational Phase 3 494-79-1
7
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
8
Pentamidine Approved, Investigational Phase 2 100-33-4 4735
9
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
10
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 54670067 5785
11
Maleic acid Experimental Phase 2 110-16-7 444266
12 Antifungal Agents Phase 2
13 Antioxidants Phase 2
14 Micronutrients Phase 2
15 Protective Agents Phase 2
16 Trace Elements Phase 2
17 Vitamins Phase 2
18
Armodafinil Approved, Investigational 112111-43-0
19
Dopamine Approved 51-61-6, 62-31-7 681
20
Methylphenidate Approved, Investigational 20748-11-2, 113-45-1 4158
21
Modafinil Approved, Investigational 68693-11-8 4236
22
Caffeine Approved, Nutraceutical 58-08-2 2519
23 Central Nervous System Stimulants
24 Cytochrome P-450 CYP3A Inducers
25 Dopamine Agents
26 Dopamine Uptake Inhibitors
27 Neurotransmitter Agents
28 Neurotransmitter Uptake Inhibitors
29 Phosphodiesterase Inhibitors
30 Purinergic P1 Receptor Antagonists
31 Wakefulness-Promoting Agents
32 Antibodies
33 Immunoglobulins

Interventional clinical trials:

(show all 22)

# Name Status NCT ID Phase Drugs
1 Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase Completed NCT00906880 Phase 4 Nifurtimox-Eflronithine Combination Treatment (NECT)
2 Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 Completed NCT01685827 Phase 2, Phase 3 Fexinidazole;Nifurtimox;Eflornithine
3 Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
4 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC Completed NCT01589289 Phase 3
5 Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Recruiting NCT03025789 Phase 3 Fexinidazole
6 Prospective Study on Efficacy and Safety of SCYX-7158 in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense Recruiting NCT03087955 Phase 2, Phase 3 SCYX 7158
7 Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study Active, not recruiting NCT02184689 Phase 2, Phase 3 fexinidazole
8 Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study Active, not recruiting NCT02169557 Phase 2, Phase 3 Fexinidazole
9 Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda Terminated NCT00489658 Phase 2, Phase 3 Eflornithine plus Nifurtimox combination therapy
10 Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
11 Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00803933 Phase 2 DB289;Pentamidine
12 A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00802594 Phase 2 DB289
13 Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia Terminated NCT00184054 Phase 2 Arsenic Trioxide (ATO);Ascorbic Acid
14 Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole Completed NCT00982904 Phase 1 Fexinidazole/Placebo
15 Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158 Completed NCT01533961 Phase 1 SCYX-7158;Placebo
16 Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions Completed NCT01340157 Phase 1 Fexinidazole
17 Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food Terminated NCT01483170 Phase 1 Tablets Fexinidazole;Placebo
18 Effects of Modafinil, Caffeine and Methylphenidate in Healthy Volunteers Completed NCT02071615 Methylphenidate 20 mg tablet given once by mouth;modafinil 200mg tablet given once by mouth;caffein 200mg tablet given once by mouth;placebo
19 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) Completed NCT01766830
20 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: Early Test-of-cure Recruiting NCT03112655
21 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection Recruiting NCT03356665
22 Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum Malaria Not yet recruiting NCT03394976

Search NIH Clinical Center for Sleeping Sickness

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: trypanosomiasis, african

Genetic Tests for Sleeping Sickness

Anatomical Context for Sleeping Sickness

MalaCards organs/tissues related to Sleeping Sickness:

38
Testes, Eye, Brain, Heart, T Cells, Pituitary, Salivary Gland

Publications for Sleeping Sickness

Articles related to Sleeping Sickness:

(show top 50) (show all 967)
# Title Authors Year
1
Sleeping sickness is a circadian disorder. ( 29302035 )
2018
2
An agent-based model of tsetse fly response to seasonal climatic drivers: Assessing the impact on sleeping sickness transmission rates. ( 29425200 )
2018
3
Oral fexinidazole for human African trypanosomiasis. ( 29353603 )
2018
4
Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT). ( 29169674 )
2018
5
Human African Trypanosomiasis in Emigrant Returning to China from Gabon, 2017. ( 29350158 )
2018
6
A Phase III Diagnostic Accuracy Study of a Rapid Diagnostic Test for Diagnosis of Second-Stage Human African Trypanosomiasis in the Democratic Republic of the Congo. ( 29246478 )
2018
7
Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. ( 29191556 )
2018
8
Do Cryptic Reservoirs Threaten Gambiense-Sleeping Sickness Elimination? ( 29396200 )
2018
9
The structure of serum resistance-associated protein and its implications for human African trypanosomiasis. ( 29358741 )
2018
10
Candidate genes-based investigation of susceptibility to Human African Trypanosomiasis in CA'te d'Ivoire. ( 29059176 )
2017
11
Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis. ( 28552771 )
2017
12
Elimination of sleeping sickness in Uganda could be jeopardised by conflict in South Sudan. ( 27955775 )
2017
13
Cell Cycle Inhibition To Treat Sleeping Sickness. ( 28928213 )
2017
14
An overlooked horticultural crop, Smyrnium olusatrum, as a potential source of compounds effective against African trypanosomiasis. ( 28087440 )
2017
15
Vertical transmission of human African trypanosomiasis: Clinical evolution and brain MRI of a mother and her son. ( 28750004 )
2017
16
Sleeping sickness can now be cured with pills. ( 29072286 )
2017
17
The socio-economic burden of human African trypanosomiasis and the coping strategies of households in the South Western Kenya foci. ( 29073144 )
2017
18
The challenging problem of disease staging in human African trypanosomiasis (sleeping sickness): a new approach to a circular question. ( 28957467 )
2017
19
Discovery and genomic analyses of hybridization between divergent lineages of Trypanosoma congolense, causative agent of Animal African Trypanosomiasis. ( 28752916 )
2017
20
Impact of the Ebola outbreak on Trypanosoma brucei gambiense infection medical activities in coastal Guinea, 2014-2015: A retrospective analysis from the Guinean national Human African Trypanosomiasis control program. ( 29131822 )
2017
21
Case of Nigeria-Acquired Human African Trypanosomiasis in United Kingdom, 2016. ( 28628444 )
2017
22
Data-driven models to predict the elimination of sleeping sickness in former Equateur province of DRC. ( 28279451 )
2017
23
The study of trypanosome species circulating in domestic animals in two human African trypanosomiasis foci of CA'te d'Ivoire identifies pigs and cattle as potential reservoirs of Trypanosoma brucei gambiense. ( 29045405 )
2017
24
Loop-Mediated Isothermal Amplification Test for Trypanosoma gambiense Group 1 with Stem Primers: A Molecular Xenomonitoring Test for Sleeping Sickness. ( 28321260 )
2017
25
Hsp70/J-protein machinery from Glossina morsitans morsitans, vector of African trypanosomiasis. ( 28902917 )
2017
26
Serological tests for gambiense human African trypanosomiasis detect antibodies in cattle. ( 29100526 )
2017
27
Including refugees in disease elimination: challenges observed from a sleeping sickness programme in Uganda. ( 29213301 )
2017
28
Delineating neuroinflammation, parasite CNS invasion, and blood-brain barrier dysfunction in an experimental murine model of human African trypanosomiasis. ( 28636879 )
2017
29
Candidate gene polymorphisms study between human African trypanosomiasis clinical phenotypes in Guinea. ( 28827791 )
2017
30
Expression of interferon-inducible chemokines and sleep/wake changes during early encephalitis in experimental African trypanosomiasis. ( 28821016 )
2017
31
Relationship between Trypanosoma brucei rhodesiense genetic diversity and clinical spectrum among sleeping sickness patients in Uganda. ( 29078807 )
2017
32
Performance of the SD BIOLINEAr HAT rapid test in various diagnostic algorithms for gambiense human African trypanosomiasis in the Democratic Republic of the Congo. ( 28672036 )
2017
33
Monitoring the elimination of human African trypanosomiasis: Update to 2014. ( 28531222 )
2017
34
Human African trypanosomiasis. ( 28673422 )
2017
35
Enhanced passive screening and diagnosis for gambiense human African trypanosomiasis in north-western Uganda - Moving towards elimination. ( 29023573 )
2017
36
Introducing the TrypanoGEN biobank: A valuable resource for the elimination of human African trypanosomiasis. ( 28570558 )
2017
37
Erratum: Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis. ( 28074881 )
2017
38
New developments in probing and targeting protein acylation in malaria, leishmaniasis and African sleeping sickness. ( 28270257 )
2017
39
Animal African Trypanosomiasis in Nigeria: A long way from elimination/eradication. ( 28870536 )
2017
40
African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase. ( 29107420 )
2017
41
Predicting the Impact of Intervention Strategies for Sleeping Sickness in Two High-Endemicity Health Zones of the Democratic Republic of Congo. ( 28056016 )
2017
42
Nanobodies As Tools to Understand, Diagnose, and Treat African Trypanosomiasis. ( 28713367 )
2017
43
Fexinidazole: A New Drug for African Sleeping Sickness on the Horizon. ( 29275007 )
2017
44
Human African trypanosomiasis control: Achievements and challenges. ( 28426685 )
2017
45
APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis. ( 28537557 )
2017
46
Adding tsetse control to medical activities contributes to decreasing transmission of sleeping sickness in the Mandoul focus (Chad). ( 28750007 )
2017
47
A polymorphism in the haptoglobin, haptoglobin related protein locus is associated with risk of human sleeping sickness within Cameroonian populations. ( 29077717 )
2017
48
The role of cytokines in the pathogenesis and staging of Trypanosoma brucei rhodesiense sleeping sickness. ( 26807135 )
2016
49
Human African Trypanosomiasis in the Kafue National Park, Zambia. ( 27196336 )
2016
50
Host Intracellular Signaling Events and Pro-inflammatory Cytokine Production in African Trypanosomiasis. ( 27242788 )
2016

Variations for Sleeping Sickness

Expression for Sleeping Sickness

Search GEO for disease gene expression data for Sleeping Sickness.

Pathways for Sleeping Sickness

Pathways related to Sleeping Sickness according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1 11.83 GAPDH IL10 IL6 TF
2
Show member pathways
11.76 AMD1 MDH2 SRM
3
Show member pathways
11.67 APOL1 HP HPR
4 11.62 IL10 IL6 NOS2
5 11.61 HSPA8 IL10 IL6 NOS2
6 11.57 MDH2 ODC1 SRM
7 11.46 IL10 IL6 NOS2
8 11.46 GAPDH IL6 NOS2 TF
9 11.36 IL10 IL6 NOS2
10
Show member pathways
11.01 AMD1 NOS2 ODC1 SRM
11
Show member pathways
10.89 ODC1 SRM
12 10.47 APOL1 HPR IL10 IL6

GO Terms for Sleeping Sickness

Cellular components related to Sleeping Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.02 APOL1 HP HPR HSPA8 TF

Biological processes related to Sleeping Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.43 IL10 IL6 NOS2
2 spermidine biosynthetic process GO:0008295 9.16 AMD1 SRM
3 polyamine biosynthetic process GO:0006596 9.13 AMD1 ODC1 SRM
4 polyamine metabolic process GO:0006595 8.8 AMD1 ODC1 SRM

Molecular functions related to Sleeping Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hemoglobin binding GO:0030492 8.62 HP HPR

Sources for Sleeping Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....